Citation: Best SR, Mohr M, Zur KB. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope. 2017;127:2225–2229.
Systemic Bevacizumab Promising for Treatment-Resistant Recurrent Respiratory Papillomatosis
by Amy E. Hamaker •
You Might Also Like:
- Systemic Use of Bevacizumab for Recurrent Respiratory Papillomatosis: Who, What, Where, When, and Why?
- Bevacizumab Infusions an Effective Adjuvant Therapy in Juvenile-Onset Recurrent Respiratory Papillomatosis
- Adjuvant Therapies May Increase Time Between Surgeries for Recurrent Respiratory Papillomatosis
- Vaccination and Medical Advancements Helping to Decrease Recurrent Respiratory Papillomatosis Incidence